CD274 and breast cancer: In addition, 1.3% of the hormone receptor (HR)-positive/HER2-negative type, 11.6% of the HER2-positive type and 27.7% of the triple-negative type were classified as PD-L1-positive breast cancer in cohort A. The median recurrence-free survival (RFS) in cohort A was 128 (range, 1–147) months.